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Composite risk and benefit from adjuvant dose-dense
chemotherapy in hormone receptor-positive breast cancer
Fabio Puglisi 1,2✉, Lorenzo Gerratana1,2, Matteo Lambertini 3,4, Marcello Ceppi5, Luca Boni 5, Filippo Montemurro 6,
Stefania Russo7, Claudia Bighin8, Michelino De Laurentiis9, Mario Giuliano10, Giancarlo Bisagni11, Antonio Durando12, Anna Turletti13,
Ornella Garrone14, Andrea Ardizzoni15, Teresa Gamucci16, Giuseppe Colantuoni17, Adriano Gravina18, Sabino De Placido10,
Francesco Cognetti19 and Lucia Del Mastro 3,20
The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better
define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of
recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite
measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox
proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values
of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP
analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles
ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph
node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6
was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a
consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied
according to CPRS.
npj Breast Cancer            (2021) 7:82 ; https://doi.org/10.1038/s41523-021-00286-w
INTRODUCTION
Although evidence support dose-dense chemotherapy in early
breast cancer (eBC), a clinical practice still varies around the world,
and few randomized clinical trials have compared the same drugs
and doses in the dose-dense and control arms1–6. Furthermore,
indirect comparison among trials could also be potentially
confounded by noncompletely comparable risk profiles across
the patients’ populations enrolled in different studies.
In the clinical decision-making process, careful analysis of
clinical and biological characteristics is crucial to identify
subgroups of patients with a favorable risk/benefit ratio associated
with the use of a dose-dense schedule. Despite the increasing
evidence supporting the use of dose-dense adjuvant chemother-
apy for patients with high-risk eBC, the association between
hormone receptor status and absolute benefit from a dose-dense
schedule remains unclear7,8.
Previous generation studies often discouraged the use of dose-
dense regimens in patients with hormone receptor-positive
tumors, restricting the recommendation to the hormone
receptor-negative subgroup7,9. The CALGB combined analysis of
trials 8541, 9344, and 9741, highlighted that dose-dense
chemotherapy was particularly effective in patients with hormone
receptor-negative eBC, whereas the benefit in patients with
hormone receptor-positive disease was smaller and not signifi-
cantly different from the standard schedule10.
The GIM2 randomized phase III trial enrolled patients with
node-positive eBC regardless of hormone receptor and
HER2 status. After a median follow-up of 7 years, the study
demonstrated an improvement both in terms of disease-free
survival (DFS) and overall survival (OS) for the dose-dense arm
(hazard ratio (HR) 0.77, 95% CI 0.65–0.92, P= 0.004 and HR 0.65,
95% CI 0.51–0.84; P= 0.001, respectively)11. Interestingly, the trial
reported a homogeneous benefit among the two hormone
receptor subgroups (P for interaction of 0.43), with an HR 0.69
for hormone receptor-negative (95% CI 0.48–0.99) and 0.80 for
hormone receptor-positive (95% CI 0.65–0.98)11.
To further refine the evidence of treatment effect in the
hormone receptor-positive subgroup and to better inform
selection in node-positive patients between dose-dense versus
standard-interval adjuvant chemotherapy, we evaluated treat-
ment benefit according to a quantitative composite measure of
recurrence risk based on clinicopathological features.
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Cohort characteristics and prognostic factors
Characteristics of the 1131 patients in the HER2-negative hormone
receptor-positive analysis population according to cohort, as
defined by chemotherapy schedule (dose-dense or standard
interval), are summarized in Table 1. The median follow-up was 6.4
years (interquartile range 3.8–7.3 years).
The overall 5-year DFS was 84.5% among patients treated with
dose-dense chemotherapy versus 81% among patients treated
with standard-interval chemotherapy (Fig. 1). The impact of
Table 1. Patients’ characteristics in the total population according to treatment arm.
Standard N (%) Dose-dense N (%) Total N (%)
All patients 586 (51.81) 545 (48.19) 1131
Age (years)
<35 21 (3.58) 9 (1.65) 30 (2.65)
35–39 43 (7.34) 39 (7.16) 82 (7.25)
40–44 86 (14.68) 71 (13.03) 157 (13.88)
45–49 103 (17.58) 95 (17.43) 198 (17.51)
≥50 333 (56.83) 331 (60.73) 664 (58.71)
Menopausal status
Premenopausal 297 (50.68) 252 (46.24) 549 (48.54)
Postmenopausal 289 (49.32) 293 (53.76) 582 (51.46)
Nodes
1–3 361 (61.60) 347 (63.67) 708 (62.60)
≥4 225 (38.40) 198 (36.33) 423 (37.40)
Tumor size (cm)
≤2 305 (52.05) 299 (54.86) 604 (53.40)
>2 279 (47.61) 244 (44.77) 523 (46.24)
Missing 2 (0.34) 2 (0.37) 4 (0.35)
ER (%)
<50 97 (16.55) 81 (14.86) 178 (15.74)
≥50 473 (80.72) 456 (83.67) 929 (82.14)
Missing 16 (2.73) 8 (1.47) 24 (2.12)
PGR (%)
<20 107 (18.26) 103 (18.90) 210 (18.57)
20–49 114 (19.45) 90 (16.51) 204 (18.04)
≥50 319 (54.44) 315 (57.80) 634 (56.06)
Missing 46 (7.85) 37 (6.79) 83 (7.34)
Histological grade
G1 39 (6.66) 51 (9.36) 90 (7.96)
G2 303 (51.71) 310 (56.88) 613 (54.20)
G3 243 (41.47) 181 (33.21) 424 (37.49)
Missing 1 (0.17) 3 (0.55) 4 (0.35)
KI-67 (%)
<14 167 (28.50) 198 (36.33) 365 (32.27)
14–19 60 (10.24) 66 (12.11) 126 (11.14)
20–25 113 (19.28) 82 (15.05) 195 (17.24)
≥26 162 (27.65) 132 (24.22) 294 (25.99)
Missing 84 (14.33) 67 (12.29) 151 (13.35)
Endocrine therapy by menopausal status
LHRH-a 2/0 (0.34/0.00) 1/1 (0.18/0.18) 4 (0.35)
Tamoxifen 86/82 (14.67/13.99) 83/91 (15.22/16.69) 342 (30.23)
LHRH-a+ tamoxifen 74/3 (12.62/0.51) 75/7 (13.76/1.28) 159 (14.05)
AI 23/84 (3.92/14.33) 11/99 (2.01/18.16) 217 (19.18)
Tamoxifen+ AI 39/94 (6.65/16.04) 35/79 (6.42/14.49) 247 ((21.83)
LHRH-a+ Tamoxifen+ AI 51/4 (8.70/0.68) 32/2 (5.87/0.36) 89 (7.86)
No endocrine therapy 9/11 (1.53/1.87) 4/5 (0.73/0.91) 29 (2.56)
Missing 13/11 (2.21/1.87) 11/9 (2.01/1.65) 44 (3.89)
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prognostic factors in terms of DFS, independently from treatment
assignment, are described in Fig. 2.
The multivariate analysis highlighted that number of positive
nodes (≥4 vs 1–3; HR 2.09, 95% CI 1.61–2.71, P < 0.001), tumor size
(>2 vs ≤2 cm; HR 1.78, 95% CI 1.36–2.34, P < 0.001) and histological
grade (respectively, G2 vs G1 and G3 vs G1; HR 2.78, 95% CI
1.13–6.80, P= 0.026; HR 2.98, 95% CI 1.20–7.40, P= 0.018) were
the most important prognostic factors in terms of DFS and thus
contributed the most to the composite measure of recurrence risk
(Table 2).
CPRS quartiles defined subgroups with differential risk and
consequent benefit from dose-dense chemotherapy
Table 3 shows the features of the 17 subpopulations identified
using the STEPP methodology. As adjacent subpopulations share
patients, an overlap in the CPRS range is present. The DFS-
oriented STEPP analysis showed different patterns of relative
treatment effect with respect to CPRS (Fig. 3a and Table 3). In
subpopulations with lower risk scores, the efficacy of dose-dense
therapy appears to be absent while for CPRS median values
around 2.20 we observed significantly reduced hazard ratios to
testify the maximum efficacy of therapy. The hazard ratio
increased in patients with a worse anamnestic profile. Overall,
DFS differed widely across CPRS quartiles ranging from 95.2% to
66.4% (Fig. 3b). Each CPRS quartile was characterized by a
different patients’ composition (Table 4). Considering the
observed and expected frequency of each cell estimated from
the two-way Table 4, the first CPRS quartile was characterized by
age between 45 and 49 years (90 observed vs 51 expected), less
than four lymph nodes involved (275 observed vs 177 expected) a
tumor size ≤2 (264 observed vs 155 expected) and a PGR > 20
(respectively, 25 observed vs 60 expected and 242 observed vs
170 expected for the PGR 20–49 and ≥50 subgroups). The second
CPRS quartile was mainly characterized by age between 40 and 49
years (105 observed vs 91 expected), less than four lymph nodes
involved (255 observed vs 177 expected), a tumor size ≤2 (182
observed vs 155 expected), and G2 (169 observed vs 154
expected) (Fig. 3c). Patients included in the third CPRS quartile
showed ≥4 lymph nodes involved (132 observed vs 106
expected), a tumor size >2 (141 observed vs 128 expected), a
PGR < 20 (69 observed vs 53 expected), and G3 (125 observed vs
107 expected) (Fig. 3c). The fourth CPRS was characterized by an
age < 40 years (respectively 12 observed vs 9 expected and 48
observed vs 21 expected for the <35 years and 35–39 years
subgroups), ≥4 lymph nodes involved (255 observed vs 105
expected) a tumor size >2 (250 observed vs 127 expected), ER < 50
(70 observed vs 45 expected), PGR < 20 (78 observed vs 52
expected), G3 (155 observed vs 106 expected), and a Ki-67 ≥ 26
(129 observed vs 83 expected) (Fig. 3c). The number needed to
treat (NNT) associated with the lowest CPRS quartile was 154,
whereas the NNT associated with the highest CPRS was 6 (Fig. 3c).
The second and third CPRS quartiles had, respectively, a NTT of 35
and 5.
The CPRS scores’ impact across treatment types was reported in
terms of 5-year and 9-year DFS (Fig. 4a, b).
DISCUSSION
The present analysis conducted within the GIM2 trial assessed the
differential benefit of adjuvant dose-dense chemotherapy in
hormone receptor-positive HER2-negative eBC patients through
a CPRS approach. By combining the prognostic impact of age,
nodal involvement, tumor size, level of ER and PGR, histological
grade, and Ki-67, 17 different CPRS-based subpopulations were
defined, and their HR heterogeneity was represented by STEPP.
The population was then stratified according to CPRS
quartiles, suggesting four different risk subgroups with
differential benefit from dose-dense adjuvant chemotherapy
and characterized by different clinical features. Of note,
analyzing the extreme percentiles, it is observed that some
variables (e.g., number of lymph nodes <4, tumor size <2 cm,
PGR > 50%, histological grade <3, Ki-67 < 20%) characterize
subpopulations with low CPRS values which correspond to a
lower therapeutic benefit. Conversely, the efficacy of the dose-
dense chemotherapy appears to be greater for subpopulations
with high CPRS values where variables such as a number of
lymph nodes ≥4, a tumor size >2 cm, and Ki-67 levels ≥20% are
mostly concentrated.
The subsequent DFS-oriented STEPP analysis showed, more-
over, an increasingly higher benefit for the dose-dense regimen
across medium–high-risk patients, with advantage mitigation for
the highest risk subgroup. On the other hand, the absolute benefit
was consistently higher in the third and the fourth CPRS quartile
(respectively, NNT 5 and 6) (Fig. 3c), compared to the first CPRS
quartile (NNT 154), a trend that was also confirmed in terms of 5-
year and 9-year DFS.
These apparently counterintuitive results could be due to a
lower relative benefit linked to the specific tumor biology of the
fourth CPRS quartile which is undifferentiated and therefore





















0 1 2 3 4 5 6 7 8 9 10
Time Since Random Assignment (years)
Standard               586                137               81.0±1.7
Dose-dense          545                105               84.5±1.7
        TREATMENT               Patients        Events      5-year DFS±SE
HR=0.81; 95%CI 0.63-1.05; p= 0.113
545 515 477 447 411 365 327 179 50 10 0Dose-dense
586 543 498 451 420 381 321 165 57 5 0Standard
Number at risk
Fig. 1 Standard vs dose-dense adjuvant chemotherapy in hormone receptor-positive early breast cancer (eBC) patients. Kaplan-Meier
survival plot showing the Disease-Free Survival of patients in the study cohort stratified by treatment.
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clinical risk of this subgroup amplifies small relative benefits in
higher absolute benefits.
The use of dose-dense chemotherapy in patients with hormone
receptor-positive has been largely debated. It is generally believed
that hormone receptor-positive tumors are intrinsically less
responsive to chemotherapy than hormone receptor-negative
tumors. In the CALGB combined analysis, the absolute benefit due
to the dose-dense schedule was greater for patients with
hormone receptor-negative disease compared with that observed
for patients with hormone receptor-positive disease10. The authors
have provided some possible explanations for these observations.
One hypothesis considered the fact that, although the che-
motherapy regimen was randomly assigned across treatment
arms, endocrine treatment was not. Different agents and
treatment compliances could randomly affect overall efficacy
and consequently alter the final conclusions. Furthermore, the risk
reduction that may be achieved with chemotherapy is difficult to
detect in the first years after treatment when the risk of relapse for
luminal subtypes is lower than in hormone receptor-negative
subgroups. Regardless, the population of hormone receptor-
positive could be heterogeneous with respect to intrinsic
sensitivity to chemotherapy.
Several studies have proposed gene expression analysis as a
means to define the benefit of chemotherapy in patients with
hormone receptor-positive HER2-negative breast cancer12.
Interestingly, an interim analysis (median follow-up: 5.1 years) of
phase 3 RxPONDER trial, presented at the San Antonio Breast
Cancer Symposium 2020, showed that adding chemotherapy to
endocrine therapy did not improve outcomes for postmenopausal
women with early-stage, node-positive, luminal breast cancer in
comparison to endocrine therapy alone. Specifically, these
findings relate to postmenopausal patients with involvement of
1–3 lymph nodes and defined as low risk on the basis of
recurrence score ≤25 on the 21-tumor gene expression assay
(Oncotype Dx). On the other hand, women with the same





















0 2 4 6 8 10
Time Since Random Assignment (years)
  <35                   30                 9                  69.1±9.2
35-39                  82                24                 74.4±5.1
40-44                157                28                 85.6±3.0
45-49                198                33                 86.4±2.6
   ≥50                 664              148                 82.6±1.6





















0 2 4 6 8 10
Time Since Random Assignment (years)
≤2                  606                 91               87.8±1.4
>2                  525               151               76.8±2.0
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Time Since Random Assignment (years)
1-3                   708               105                89.2±1.2
 ≥4                   423               137                71.8±2.3
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Time Since Random Assignment (years)
G1                   90                  5                 97.0±2.1
G2                  615              127                 83.8±1.6
G3                  426              110                 78.5±2.1
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Time Since Random Assignment (years)
<50             181                  48                 78.0±3.3
≥50             950                 194                 83.6±1.3
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Time Since Random Assignment (years)
 <20                   211                  57                78.9±3.0
20-49                 240                  62               77.0±2.9
  ≥50                   680                123               85.9±1.4





















0 2 4 6 8 10
Time Since Random Assignment (years)
 <14                    381               65                87.5±1.8
14-19                 174               38                 81.1±3.2
20-25                 244               53                 82.4±2.6
  ≥26                  332                86                78.3±2.4




Fig. 2 Prognostic factors. Kaplan-Meier plot of DFS independently from treatment assignment in terms of age (a), tumor size (b), nodal status
(c), Q9 histological grade (d), ER (e), PGR (f), and Ki-67 (g).
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from chemotherapy, probably as a result of the endocrine effect of
chemotherapy-induced ovarian suppression13.
Although gene expression analysis was not performed in
patients of the GIM2 trial, it seems reasonable to assume that
the estimation of the benefit from adding chemotherapy to
endocrine therapy in low risk (i.e., recurrence score ≤25)
patients also applies to dose-dense chemotherapy. Of note, a
pooled analysis of two randomized clinical trials that evaluated
the efficacy of adjuvant dose-dense chemotherapy in pre-
menopausal breast cancer patients did not show an increased
risk of treatment-induced amenorrhea with dose-dense che-
motherapy14. Therefore, in premenopausal patients, it is
difficult to hypothesize a greater chemo-induced endocrine
effect of dose-dense chemotherapy compared to standard-
interval chemotherapy.
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
patient-level meta-analysis further dissected the role of dose-
dense adjuvant regimens in eBC15. The pooled data of 37,298
women enrolled in 26 different randomized trials were analyzed,
with recurrence and breast cancer mortality as primary out-
comes. In the total population, dose-intense strategies were
associated with a reduction of both recurrences (RR 0.86; 95% CI
0.82–0.89; P < 0.0001) and breast cancer mortality (RR 0.86;
95% CI 0.77–0.96). Recurrence reduction was similar in hormone
receptor-negative and hormone receptor-positive eBC patients
(RR 0.82; 95% CI 0.71–0.95 and RR 0.83, 95% CI 0.75–0.93,
respectively), while a slightly different delta was highlighted in
terms of 10-year recurrence (3.7% vs 3.1% in hormone receptor-
negative and hormone receptor-positive eBC patients, respec-
tively), consistently with the assumption that, at the same level of
relative risk reduction, higher-risk groups experience a greater
absolute benefit.
In fact, while acknowledging the value of the EBCTG meta-
analysis, we conducted an exploratory analysis of the GIM2 study
in order to understand granularly how the different variables
contribute to the risk of relapse and the consequent estimate of
the therapeutic benefit based on that risk.
Table 2. Multivariate Cox regression model stratified by treatment for
the variables used by composite risk score assessment.
Log (HR) HR 95% CI P value
Age
<35 0.425 1.53 0.72–3.24 0.268
35–39 0.859 2.36 1.39–3.99 0.001
40–44 0.113 1.12 0.68–1.84 0.665
45–49 0.000 1.00 Ref.
≥50 0.322 1.38 0.94–2.03 0.100
Nodes
1–3 0.000 1.00 Ref.
≥4 0.737 2.09 1.61–2.71 <0.001
Tumor size
≤2 0.000 1.00 Ref.
>2 0.577 1.78 1.36–2.34 <0.001
ER (%)
<50 0.262 1.30 0.92–1.82 0.135
≥50 0.000 1.00 Ref.
PGR (%)
<20 0.293 1.34 0.96–1.86 0.083
20–49 0.140 1.15 0.82–1.62 0.418
≥50 0.000 1.00 Ref.
Histological grade
G1 0.000 1.00 Ref.
G2 1.022 2.78 1.13–6.80 0.026
G3 1.092 2.98 1.20–7.40 0.018
Ki-67 (%)
<14 0.000 1.00 Ref.
14–19 0.166 1.18 0.75–1.85 0.483
20–25 0.068 1.07 0.72–1.58 0.741
≥26 0.095 1.10 0.77–1.57 0.605
The missing values were estimated using the multiple imputation method.
Table 3. Prognosis across composite risk score subpopulations.
Subpopulation Size Median CPRS Minimum CPRS Maximum CPRS HR 95% CI
1 302 1.23 0.00 1.49 0.96 0.38–2.42
2 300 1.34 0.70 1.59 0.90 0.41–1.94
3 301 1.42 1.12 1.70 0.89 0.44–1.82
4 302 1.51 1.26 1.82 1.08 0.56–2.07
5 304 1.62 1.36 1.92 1.06 0.60–1.89
6 300 1.76 1.44 2.03 0.94 0.54–1.62
7 306 1.87 1.52 2.08 0.86 0.50–1.46
8 300 1.96 1.65 2.15 0.78 0.45–1.34
9 301 2.04 1.78 2.22 0.85 0.52–1.41
10 302 2.08 1.88 2.34 0.71 0.43–1.16
11 300 2.15 1.97 2.45 0.55 0.33–0.91
12 301 2.23 2.06 2.61 0.47 0.28–0.78
13 300 2.37 2.09 2.75 0.48 0.30–0.77
14 305 2.47 2.16 2.82 0.66 0.43–1.03
15 303 2.65 2.27 2.96 0.79 0.52–1.20
16 300 2.78 2.38 3.29 0.81 0.54–1.21
17 273 2.82 2.49 3.91 0.91 0.61–1.38
CPRS composite risk score, HR hazard ratio.
Subgroups were defined according to the median composite risk score, interaction P value based on hazard ratio estimates: 0.3084.
F. Puglisi et al.
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With a median follow-up of 7 years, GIM2 is the dose-dense
focused trial with the longest follow-up and is therefore the best
candidate to better explore tailored treatment strategies in
hormone receptor-positive eBC. By combining well-established
prognostic factors in a CPRS, the present analysis was capable to
represent risk as a continuous variable and to identify and
describe specific risk subgroups that could have a differential
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Time Since Random Assignment (years)
1st                    283                 18                 95.2±1.4
2nd                    283                48                 88.1±2.1
3rd                     284                69                 81.0±2.5
4th                     281               107                66.4±3.0
        CPRS Quartiles       Patients        Events      5-year DFS±SE









































































































































Age: 45 - 49 y 


















































































































































Age: 45 - 49 y 
Lymph nodes: < 4 
T: ≤ 2cm
PGR: > 20%
Fig. 3 DFS-oriented STEPP analysis. (a), CPRS quartiles and prognosis in terms of DFS and 5-year DFS (b), disease-free survival according to
Median Composite Score (c). To smooth the DFS curve and its pointwise confidence interval the LOWESS method with a bandwidth of 0.80
Q10 was applied. Overall, DFS differed widely across CPRS quartiles (b), with the number needed to treat (NNT) associated with the lowest
CPRS quartile of 154 vs 6 for the highest quartile (c). Notably, the first CPRS quartile was characterized by age between 45 and 49 years, less
than four lymph nodes involved, tumor size ≤2, and a PGR > 20 (c). The fourth CPRS was characterized by an age <40 years, ≥4 lymph nodes
involved a tumor size >2, ER < 50, PGR < 20, G3, and a Ki-67 ≥ 26 (c). The 25th and the 75th percentiles are represented by the dashed lines.
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quartile 4 is characterized by specific biological characteristics that
confer a potentially chemosensitive phenotype and are typically
associated with a luminal B-like profile, such as low ER and PGR
levels and high KI67. Notably, the association with younger age
could have intriguing biological implications16. It has been
previously reported that breast cancer of the young, particularly
the hormone receptor-positive subtype, is a peculiar biological
entity that can differ from the older counterpart in several
molecular aspects and in particular through the enrichment of
biological processes related to stemness and growth factor
signaling and the downregulation of apoptosis-related genes17.
These aspects could deeply affect the tumors’ response to
chemotherapy which could justify the need for a more dose-
intense treatment schedule14.
Dose-dense adjuvant chemotherapy showed a consistent
benefit in node-positive eBC patients with hormone receptor-
positive HER2-negative disease, but its effect varied according to
CPRS. Therefore, dose-dense adjuvant chemotherapy should be
taken into consideration also in the hormone receptor-positive
subgroup. This study offers a potential hint towards a tailored
approach based on broader multiparametric criteria, capable of




The GIM2 is a multicenter, randomized phase 3 trial, with a 2 × 2
factorial design aiming to address both the role of the addition of
fluorouracil to epirubicin, cyclophosphamide, and paclitaxel and the
role of the dose-dense schedule in the adjuvant treatment of patients
with node-positive eBC11.
The study population included 2198 patients from 81 Italian centers. The
primary endpoint was DFS, defined as the time from random assignment
to local or distant recurrence, contralateral or ipsilateral breast tumor
(excluding ductal carcinoma in situ), second primary malignancy, death
from any cause, and loss to follow-up or end of the study, whichever
came first.
As a sub-analysis of the GIM2 randomized multicenter clinical trial, the
study was approved by ethics committees of all participating institutions.
Written informed consent was obtained from all patients before study
entry. Participating centers and principal investigators are listed in
Supplementary Data 1.
Composite risk score analysis
The present analysis examined the absolute treatment effect through a
composite measure of recurrence risk to better individualize the clinical
algorithm in the choice between dose-dense and standard-interval
chemotherapy in patients with hormone receptor-positive HER2-negative
eBC (N= 1131).
Patients with hormone receptor-positive HER2-positive eBC were
excluded from the current analysis to avoid the potential confounding
effect of trastuzumab use in only a minority of these patients and the
differential observed benefit of dose-dense chemotherapy in this
subgroup18.
Applying to hormone receptor-positive HER2-negative patients the Cox
proportional hazards model, the risk of recurrence (hazard ratio) related to
each prognostic factor of the patients was estimated, such as age (<35,
35–39, 40–44, 45–49, ≥50 years), number of positive nodes (1–3, ≥4), tumor
size (≤2, >2 cm), estrogen receptor (ER, < 50%, ≥50%), progesterone
receptor (PGR, < 20%, 20–49%, ≥50%), histological grade (1, 2, 3), KI67
( < 14%, 14–19%, 20–25%, ≥26%). The groupings of prognostic factors
followed the usual clinical cut-points as defined by the St Gallen Consensus
statements with the exception of estrogen receptor due to the low
number of patients with values less than 10% (n= 31) and KI67 where a
high proportion of patients (n= 294) showed values equal to or greater
than 2619. Multiple Imputation procedure was applied to handle missing
values20,21. The CPRS was then computed, for each patient, through the
equation CPRS= β1X1+… + βnXn (1). In Eq. (1) for each prognostic factor,
βi is the logs (hazard ratio) and Xi is an indicator variable taking value 1 if
the factor is present and 0 otherwise. Thus, the CPRS was estimated as the
sum of the logs (hazard ratio) of the prognostic factors of each patient. We
explored the treatment effect compared to the values of CPRS by using the
Sub-population Treatment Effect Pattern Plot (STEPP) process21. Propor-
tional hazards assumption was satisfied before and after multiple
imputation22. The number needed to treat (NNT) was computed as the
reciprocal of the difference between the absolute risks of failure in the
dose-dense and standard therapy arms, respectively.
Patients were ordered from the lowest to the highest value of CPRS. Two
quantities were chosen: N1, the size of the cohorts, and N2 the maximum
number of patients shared by two cohorts where N1 > N2. The process
began with the cohort of first N1 patients in the ordered list. At the next
step, the N2 patients with the highest values of the CPRS in the previous
cohort were moved to a new cohort in addition to the N1–N2 patients that
followed in the ordered list. The process ended when all patients were
included in at least one cohort. In this analysis, it was chosen N1= 300 and
N2= 250. For each cohort, the HR relative to treatment was estimated. The
heterogeneity of HRs along the cohorts defined by STEPP analysis was
tested by means of permutation test23.
Statistical analysis was performed using R (The R Foundation for
Statistical Computing. version 3.3.1 (2016-06-21)) and STATA (StataCorp.
(2015) Stata Statistical Software: Release 14.2. College Station, TX:
StataCorp LP) software packages.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
Table 4. Distribution of composite risk score according to the
clinicopathological features used for the score assessment.
CPRS quartiles
1st 2nd 3rd 4th
Age
<35 5.71 25.71 34.29 34.29
35–39 0.00 15.12 29.07 55.81
40–44 32.30 28.57 19.25 19.88
45–49 44.55 29.21 14.36 11.88
≥50 21.48 24.11 28.90 25.50
Nodes
1–3 38.84 36.02 21.47 3.67
≥4 1.89 6.62 31.21 60.28
Tumor size
≤2 42.58 29.35 23.06 5.00
>2 3.72 19.77 27.59 48.92
ER (%)
<50 11.60 22.10 27.62 38.67
≥50 27.58 25.58 24.63 22.21
PGR (%)
<20 7.58 22.75 32.70 36.97
20–49 10.42 27.08 29.58 32.92
≥50 35.59 25.00 21.18 18.24
Histological grade
G1 88.89 6.67 3.33 1.11
G2 26.83 27.48 25.37 20.33
G3 8.92 25.35 29.34 36.38
Ki-67
<14 38.32 24.67 21.00 16.01
14–19 24.14 30.46 23.56 21.84
20–25 21.72 25.00 31.56 21.72
≥26 12.65 22.59 25.90 38.86
F. Puglisi et al.
7
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)    82 
DATA AVAILABILITY
The data generated and analyzed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.1454732124. The data are contained
in two Excel spreadsheets: “Patient survival data.xlsx” and “Patient baseline, tumour
and treatment data.xlsx”. These spreadsheets are housed on institutional storage and
are not publicly available for the following reason: data contain information that
could compromise research participant privacy. However, the data can be made
available upon reasonable request to the corresponding author. The dataset analyzed
during this study is described with more details in the following manuscript: https://
doi.org/10.1016/S0140-6736(14)62048-111.
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Fig. 4 Prognostic impact across treatment types according to CPRS score. Graphical representation of the outcome in terms of 5-year (a)
and 9-year DFS (b).
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